Clinical Trial: ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07454226) titled 'ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL' on Feb. 26.

Brief Summary: This open-label, non-randomized, single-arm, phase II exploratory study aims to evaluate the efficacy and safety of combining pathway-specific tyrosine kinase inhibitors with chemotherapy and venetoclax in patients with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL). Patients are stratified by genetic alteration: those with ABL class fusions (ABL1, ABL2, PDGFRA, PDGFRB) receive olverembatinib, while those with JAK pathway alterations (CRLF2 rearrangement, JAK mutation/fusion, EPOR fusion, SH2B3 deletion, IL7R mutation) receive...